Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
Conversations With the Experts: Management of Iron Overload
In this video, a panel of four international experts discusses recent advances in understanding the pathophysiology of iron overload and progress in managing this condition in patients with thalassaemia, myelodysplastic syndromes, rare anaemias, sickle cell disease, and hereditary haemochromatosis. The discussion includes relevant reports presented at the 13th meeting of the European Haematology Association in Copenhagen, Denmark.
|
|
Chair
|
|
|
John B. Porter, MA, MD, FRCP
Professor, Department of
Haematology
University College London
London, United Kingdom
|
|
|
Faculty
|
|
|
Pierre Brissot, MD
Professor of Medicine
Liver Disease Department
University Hospital Pontchaillou
Rennes, France
|
|
|
|
Aristoteles A.N. Giagounidis, MD, PhD
St. Johannes Hospital
Medizinische Klinik II
Duisburg, Germany
|
|
|
|
Ali T. Taher, MD
Professor
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon
|
|
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Apply up-to-date information on the pathophysiology of iron overload in patients with thalassemia, myelodysplastic syndrome, to identify patients who are at risk of iron overload and should be considered candidates for iron chelation therapy.
- Utilize an understanding of the underlying pathophysiology of iron overload to determine the appropriate modality/pharmaceutical agent for iron chelation therapy in patients with thalassemia, myelodysplastic syndromes, rare anaemias, sickle cell disease, and hereditary hemochromatosis.
- Utilize an understanding of recent efficacy and safety trial data on the use of iron chelation therapy to develop treatment strategies that improve cardiac iron levels in patients with iron overload.
|
Disclosure Information
John B. Porter, MA, MD, FRCP, has received grant/research support from and is on the speakers bureau of Novartis Pharmaceuticals Corporation; and is a consultant for Genzyme Corporation, Resonance Health Ltd, and Novartis Pharmaceuticals Corporation. Prof. Porter has disclosed that he will reference the unlabeled/unapproved uses of deferiprone combined with desferrioxamine, and deferasirox.
Pierre Brissot, MD, has received grant/research support from and is on the speakers bureau of Novartis Pharmaceuticals Corporation. Prof. Brissot has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
Aristoteles A.N. Giagounidis, MD, PhD, is on the speakers bureau of Celgene Corporation; is on advisory boards for Novartis Pharmaceuticals Corporation and Pharmion Corporation; and is a stock shareholder in Hoffmann-La Roche Inc. Dr. Giagounidis has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
Ali T. Taher, MD, is on the speakers bureau of and on the advisory board for Novartis Pharmaceuticals Corporation.
|
|
|
|
|
|
|
